Guard Therapeutics International AB

Guard Therapeutics International AB, a biotechnology company, focuses on developing pharmaceutical treatments for the prevention and management of acute kidney injuries. Its flagship product, RMC-035, is a pioneering drug candidate aimed at reducing kidney damage during major surgeries and situations involving intensified medical treatments. By targeting the oxidative and inflammatory processes that contribute to renal impairment, this asset holds promising potential in improving patient outcomes in critical medical procedures. Guard Therapeutics operates primarily in the healthcare industry, impacting hospital treatment protocols and clinical healthcare practices. Its research and development efforts are central to the global push for innovative therapeutic solutions to organ injury, a significant concern in health systems worldwide. The company's advancements in biotechnology place it in a critical role within the pharmaceutical and healthcare sectors, where there is a growing demand for novel treatments that address acute clinical conditions. Based in Sweden, Guard Therapeutics champions medical innovation with a focus on organ protection, contributing substantially to the expanding field of preventive kidney care through both direct product development and influential research collaborations.